Case Studies
26.04.2023
Gaining payer insights

Our client wanted to understand the clinical and economic evidence requirements that drive payer dec...

Read more
Case Studies
26.04.2023
Gaining payer insights

Our client required focused payer value messages for their orphan drug as payers were not recognizin...

Read more
Case Studies
26.04.2023
Biosimilar country pricing and market access

Our client wanted to gain a better understanding of current and forthcoming policy measures affectin...

Read more
Case Studies
26.04.2023
Partnered with a biosimilar company

Development and submission of payer communication materials and pricing and reimbursement dossiers f...

Read more
Articles
20.04.2023
EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

Read more
Articles
13.04.2023
What are Joint Scientific Consultations and why th...

We explore joint scientific consultations; what they mean and why they are important to manufacturer...

Read more
Articles
03.04.2023
What is the joint clinical assessment and what doe...

We explore what the joint clinical assessment (JCA) is, its process and what future developments may...

Read more
News
30.03.2023
PMA Insights: Week 13 SPECIAL EDITION – Worl...

We summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...

Read more
Insider Insights
09.03.2023
Fimea launches pilot procedure for the evaluation ...

Fimea program aims to standardise the initiation of assessment which are currently different for out...

Read more
Insider Insights
06.03.2023
The Project Orbis initiative

The Project Orbis initiative is an international partnership between medicines regulators in the UK,...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.